Brenda Y Hernandez

Has grant

University of Hawaii
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Cyanobacteria, cyanotoxins, and liver cancer development

Open Date: 2024-05-01

Close Date: 2029-04-30

Grant: Close

Hawaiʻi Translational Cancer Research Program

Open Date: 2023-09-19

Close Date: 2026-07-31

Grant: Close

NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2020 BREAST CANCER AND COLORECTAL CANCER

Open Date: 2022-12-23

Close Date: 2023-12-22

Grant: Close

NCI PATTERNS OF CARE (POC)/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2019 (URINARY BLADDER CANCER AND KIDNEY CANCER)

Open Date: 2021-04-05

Close Date: 2022-04-04

Grant: Close

SEER-LINKED PEDIATRIC CANCER WHOLE SLIDE IMAGING PILOT - UNIVERSITY OF HAWAII HHSN261201800011I POP 8/20/2020-8/19/2021

Open Date: 2020-08-20

Close Date: 2021-08-19

Articles (32)

Year:

2026

In the 2021 Report on Carcinogens, the National Toxicology Program of the United States listed 63 known human carcinogens. While many of the listed agents are environmental factors, only 2, aflatoxin and vinyl chloride, have been definitely linked to types of liver cancer. Aflatoxin is well known to increase the risk of HCC, while vinyl chloride is a cause of angiosarcoma of the liver. A number of other environmental factors have been studied for an association with liver cancers, such as air pollution, perfluoroalkyl and polyfluoroalkyl substances, cyanobacteria, pesticides, aristolochic acid, polycyclic aromatic hydrocarbons, asbestos, arsenic, and organic solvents; however, limited evidence exists for these exposures. It is the goal of this review article to examine what is currently known about environmental risk factors and liver cancer and suggest which ones should have the highest priority for further research.

Year:

2025

Background: Worldwide trends support the increasing contribution of hepatic steatosis to the incidence of hepatocellular carcinoma (HCC). This study investigates if similar changes are seen in Hawaii, where the incidence of HCC is higher than in most of the United States. Methods: This is a retrospective study of 1,651 patients diagnosed with HCC (1991–2023) that includes 60% to 70% of HCC cases in Hawaii. We evaluated changes in patient demographics, risk factors, and disease etiology over the past three decades. Results: From 1991 to 2023, there were significant increases in the proportion of HCC cases attributable to metabolic dysfunction–associated steatotic liver disease (MASLD), coinciding with an increase in the prevalence of metabolic risk factors including obesity, diabetes, hyperlipidemia, and hypertension. Cases with a history of smoking also increased through 2020. Conversely, HCC cases presenting with cirrhosis alone decreased. Hepatitis C virus (HCV)-associated cases increased through 2015 and then tapered, whereas Hepatitis B virus (HBV)-associated cases decreased through 2020. There was no significant change in the proportion of alcohol-associated cases. Conclusions: Although HBV continues to be a major contributor to HCC in Hawaii, HCV-related HCC cases have tapered, whereas metabolic risk factors for HCC and cases attributable to MASLD have increased over time, paralleling overall trends observed in the United States. Efforts are needed to manage these metabolic factors to address the burden of HCC. Impact: Although Hawaii continues to have a large burden of viral hepatitis–related HCC, metabolic factors and MASLD have affected the pathogenesis of liver cancer in Hawaii over the past three decades.

Year:

2025

Supplementary Table 1. The average of the sum of pathology reports during March to May of 2018 and 2019 (pre-pandemic period) compared to the sum of pathology reports during March to May 2020 (pandemic period) by cancer site.

Year:

2025

Figure S1. Pathology report volume in 2020 compared to the volume of COVID-19 cases by geographic region and month. 1Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2023, March 27.

Year:

2025

Background: Filipino Americans constitute 12% and 4% of the respective populations of Hawaii and California, with a large proportion of immigrants experiencing increasing cancer rates. This study investigated the incidence of colorectal, breast, and prostate cancers by generational status in the Multiethnic Cohort. Methods: We analyzed 10,495 Filipino Multiethnic Cohort first-, second-, and third-generation participants, in which 26.8% were of mixed race and ethnicity. Linkage to statewide cancer registries identified 375 breast, 249 colorectal, and 436 prostate cancer incident cases. Cox models were used to calculate HRs and 95% confidence intervals (CI) for the association between generational status and cancer incidence. Models were adjusted for age at cohort entry and cancer-specific covariates that were chosen based on stepwise regression. Results: Compared with the first generation, colorectal cancer showed a significantly higher incidence in the second and third generations with respective HRs of 1.43 (95% CI, 1.04, 1.98) and 1.76 (95% CI, 1.29, 2.38). This association was attenuated after adjustment for relevant covariates. Breast cancer incidence was elevated in the third versus first generation (HR = 1.29; 95% CI, 1.01, 1.63) even in the fully adjusted model, whereas little difference was observed for prostate cancer. Conclusions: In this prospective study, we found differences in incidence by generational status, specifically colorectal cancer among men and female breast cancer. Impact: Understanding behavioral changes due to acculturation is warranted to mitigate cancer risks in migrant populations.

Year:

2024

Year:

2024

Year:

2024

Current characteristics of early onset colorectal cancer (EOCRC) in the United States have been mainly studied in Whites, African Americans, and Hispanics, but little is known in regard to EOCRC in Asians and Native Hawaiians in the US. EOCRC was examined in Hawaii’s multiethnic population. Data from the Hawaii Tumor Registry was used to analyze colorectal cancer (CRC) cases diagnosed in Hawaii from 2000–2019 by subsite, age, gender, ethnicity, and stage. Ethnicity analyses were limited to 3524 CRC cases, diagnosed between 2015–2019. Average annual 5-year age-adjusted incidence and mortality rates, average annual percent change over time, and 5-year survival were evaluated. Group comparisons utilized Chi-square and binomial proportion tests. Overall CRC incidence and mortality declined and were more pronounced for colon than rectal/rectosigmoid junction cancers. Colon cancer incidence rates significantly increased 1.46-fold for cases diagnosed under 45 years of age and rectal/rectosigmoid cancers significantly increased 1.54-fold for cases 45–54 years of age. CRC incidence increased sharply for females aged 45–54 years from 2000–2009 to 2010–2019, and increases in colon and rectal/rectosigmoid cancer among individuals aged 45–54 were higher for females. Among both sexes, the increase in rectal/rectosigmoid cancer incidence for individuals under 55 years was highest for stage I cancers. Overall, the mean (SD) age of CRC diagnosis was 5–10 years earlier for Native Hawaiians (60.6 [13.3] years) compared with Japanese, Chinese, Filipinos, Whites, and Other Asians (p < 0.001). Native Hawaiians constituted a greater proportion of CRC diagnosed under age 55 years and, conversely, a smaller proportion of cases 55 years and older compared with Japanese, Chinese, Filipinos, Whites, and Other Asians. Native Hawaiians had a significantly higher CRC-related mortality rate (14.5 per 100,000 [95% CI: 12.4, 16.8]) compared with Japanese (10.7 per 100,000 [95% CI: 9.3, 12.3]) and a significantly lower CRC survival rate (62.2% [95% CI: 59.1, 65.2]) compared with Japanese (71.9% [95% CI: 69.9, 73.8]), Filipinos (71.9% [95% CI: 69.2, 74.4]), Chinese (70.2% [95% CI: 65.5, 74.4]), Whites (69.3% [95% CI: 67.1, 71.4]), and Other Asians (71.7% [95% CI: 66.2, 76.5]). In our diverse US population, Native Hawaiians contribute disproportionately to EOCRC and present 5–10 years earlier than Whites, Japanese, Chinese, and Filipinos. EOCRCs are increasing faster in females than males in Hawaii, which differs from trends in the general US population. Emerging ethnic disparities in EOCRC in the US speak to the need for studies on targeted interventions and ethnic-specific risk factors for EOCRC.

Year:

2024

Background: Filipino Americans constitute 12% and 4% of the respective populations of Hawaii and California, with a large proportion of immigrants experiencing increasing cancer rates. This study investigated the incidence of colorectal, breast, and prostate cancers by generational status in the Multiethnic Cohort. Methods: We analyzed 10,495 Filipino Multiethnic Cohort first-, second-, and third-generation participants, in which 26.8% were of mixed race and ethnicity. Linkage to statewide cancer registries identified 375 breast, 249 colorectal, and 436 prostate cancer incident cases. Cox models were used to calculate HRs and 95% confidence intervals (CI) for the association between generational status and cancer incidence. Models were adjusted for age at cohort entry and cancer-specific covariates that were chosen based on stepwise regression. Results: Compared with the first generation, colorectal cancer showed a significantly higher incidence in the second and third generations with respective HRs of 1.43 (95% CI, 1.04, 1.98) and 1.76 (95% CI, 1.29, 2.38). This association was attenuated after adjustment for relevant covariates. Breast cancer incidence was elevated in the third versus first generation (HR = 1.29; 95% CI, 1.01, 1.63) even in the fully adjusted model, whereas little difference was observed for prostate cancer. Conclusions: In this prospective study, we found differences in incidence by generational status, specifically colorectal cancer among men and female breast cancer. Impact: Understanding behavioral changes due to acculturation is warranted to mitigate cancer risks in migrant populations.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (50)

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Timothy Budden

Lecturer

University of Liverpool

UNITED KINGDOM
View details

John Groopman

Edith Schoenrich Professor of Preventive Medicine

Johns Hopkins University

UNITED STATES
View details

Beth Karlan

Vice Chair

University of California, Los Angeles

UNITED STATES
View details

Anna Jakubowska

Head

Pomeranian Medical University

POLAND
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Anthony Swerdlow

Professor of Epidemiology

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Martin Widschwendter

Professor; Director

University of Innsbruck

AUSTRIA
View details

Martin Köbel

Associate Professor

University of Calgary

CANADA
View details

Scarlett L. Gomez

University of California, San Francisco

UNITED STATES
View details

Song-Yi Park

-

UNITED STATES
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Cezary Cybulski

Pomeranian Medical University

POLAND
View details

Grazyna Badowski

U54 NCI grant Biostatistics Shared Resource Core leader

University of Guam

UNITED STATES
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Xun Shi

Professor

Dartmouth College

UNITED STATES
View details

Angela Brooks-Wilson

Simon Fraser University

CANADA
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Joellen Schilkdraut

Professor

Emory University

UNITED STATES
View details

Michael Anglesio

Associate Professor

The University of British Columbia

CANADA
View details

Ramona Erber

W2-Professorin, Oberärztin

University of Regensburg

GERMANY
View details

Usha Menon

Professor of Gynaecological Oncology

University College London

UNITED KINGDOM
View details

Huann-Sheng Chen

National Institutes of Health

UNITED STATES
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Cheng-Han Lee

Associate Professor

University of Alberta

CANADA
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

C Blake Gilks

-

CANADA
View details

Peter Fasching

-

GERMANY
View details

Francesmary Modugno

University of Pittsburgh

UNITED STATES
View details

Alexander Hein

-

GERMANY
View details

Dale Garsed

University of Melbourne

AUSTRALIA
View details

Renée Fortner

Head of Division

Deutsches Krebsforschungszentrum

GERMANY
View details

K Sundfeldt

Professor/Consultant

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

Gertraud Maskarinec

Professor and Associate Director for Research Education

University of Hawaii

UNITED STATES
View details

Gregg Nelson

Gynecologic Oncologist

University of Calgary

CANADA
View details

Loic Le Marchand

Professor

University of Hawaii

UNITED STATES
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Michael Edwin Jones

Senior Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Daniel E Spratt

Chair

University Hospitals Seidman Cancer Center

UNITED STATES
View details

Jan Lubiński

Head of Dept

Pomeranian Medical University

POLAND
View details

Veronica Setiawan

Associate Professor

University of Southern California

UNITED STATES
View details

Mona El-Bahrawy

Imperial College London

UNITED KINGDOM
View details

Aleksandra Gentry-Maharaj

University College London

UNITED KINGDOM
View details

David G. Huntsman

The University of British Columbia

CANADA
View details

Mindy DeRouen

Assistant Professor

New Mexico State University

UNITED STATES
View details

Susan Ramus

Professor of Molecular Oncology

University of New South Wales

AUSTRALIA
View details

Aline Talhouk

Assistant Professor

The University of British Columbia

CANADA
View details

Stephen Schwartz

Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details